Outlook Therapeutics (OTLK) Earnings Date & Reports

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

OTLK is expected to report earnings to rise 22.92% to -98 cents per share on May 15

Outlook Therapeutics OTLK Stock Earnings Reports

Q1'24

Est.

$-0.98

Q4'23

Beat

by $0.19

Q3'23

Missed

by $0.94

Q2'23

Missed

by $1.55

Q1'23

Missed

by $0.54

The last earnings report on February 14 showed earnings per share of -80 cents, beating the estimate of -99 cents. With 212.33K shares outstanding, the current market capitalization sits at 50.56M.

View a ticker or compare two or three

Compare

OTLK